ライフサイエンスコーパス: anosmia

1 function (normosmia > hyposmia > functional anosmia).

2 (range, 0-6; lower score indicating greater anosmia).

3 % CI, 0.005-0.062) m/s slower for those with anosmia.

4 humans may be involved in CRSwNP-associated anosmia.

5 ents, or of the loss of sensory input due to anosmia.

6 al intervention for improving post-traumatic anosmia.

7 various therapeutics for SARS-CoV-2-related anosmia.

8 e has been little exploration of hyposmia or anosmia.

9 nificantly associated with increased odds of anosmia.

10 e exhibited prodepression phenotypes without anosmia.

11 e 15 men who had a sustained reversal, 4 had anosmia.

12 UBR3-/- mice had female-specific behavioral anosmia.

13 ndividuals with BBS have partial or complete anosmia.

14 les, 22 to 36 years of age, with and without anosmia.

15 O4, as generally practiced, does not produce anosmia.

16 cluding 321 (23.0%) with severe microsmia or anosmia.

17 ncluding 128 (8.2%) with severe microsmia or anosmia.

18 ans leads to profound pain insensitivity and anosmia.

19 igns of clinical disease, it did not prevent anosmia.

20 0.007-0.013) m/s/year faster for those with anosmia.

21 One patient suffered from anosmia.

22 11-12), moderate (9-10), hyposmia (7-8), or anosmia (0-6).

23 ce, 4%; 95% CI, 1% to 6%) and have objective anosmia (15% vs 13%; difference, 2%; 95% CI, 0.1% to 4%)

24 sisting of 25 with post-traumatic functional anosmia, 16 with post-traumatic hyposmia, and 22 healthy

25 he symptoms with the highest prevalence were anosmia (43.1% (95% CI 35.2% to 51.3%), n=15 975, 63 stu

26 algia (16.9%; 7.6%), dysgeusia (7.4%; 1.9%), anosmia (6.0%; 2.2%) and seizure (1.1%; 5.2%).

27 t symptoms among non-hospitalized women were anosmia [63% pregnant, 92% non-pregnant] and headache [7

28 ousal, and neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, par

29 (56.3%) were the most common symptoms, while anosmia/ageusia affected 9% of patients.

30 These findings suggest that anosmia/ageusia may be associated with less severe disea

31 Those with anosmia/ageusia were younger, had lower BMI, lower syste

32 The association of anosmia/ageusia with a positive severe respiratory syndr

33 V-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls.

34 pite ethnic differences in the prevalence of anosmia/ageusia, our study highlights similar clinical p

35 9 patients in Taiwan, focusing on those with anosmia/ageusia.

36 The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02-8.39), hair loss (3.99, 3

37 Anosmia and ageusia are common, and can occur in the abs

38 gly associated with infection, together with anosmia and ageusia.

39 mitter release is the principal mechanism of anosmia and analgesia in mouse and human Nav1.7-null mut

40 ften accompanied by neurological symptoms of anosmia and fatigue.

41 lead to Kallmann syndrome, characterized by anosmia and hypogonadotrophic hypogonadism.

42 Anosmia and hyposmia severely impact the physical, emoti

43 However, other phenotypes, such as anosmia and obesity, which are typically associated with

44 ann syndrome (KS), which is characterized by anosmia and pubertal failure due to hypogonadotropic hyp

45 tely strong correlation between the level of anosmia and the score of histological damage within the

46 tely strong correlation between the level of anosmia and the thickness of the olfactory epithelium, p

47 Furthermore, treatments used to induce anosmia and to disrupt magneto-reception in displacement

48 y symptoms of fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body

49 45% in the lowest quartile of UPSIT scores (anosmia) and 18% in the highest quartile of UPSIT scores

50 amilies, one with Kallmann syndrome (IHH and anosmia) and another with normosmic IHH, in which a sing

51 (range, 0-14; lower score indicating greater anosmia) and NASAL-3 (range, 0-6; lower score indicating

52 in olfactory sensory neurons (OSNs) leads to anosmia, and is a newly recognized clinical manifestatio

53 thic hypogonadotropic hypogonadism (IHH) and anosmia, and is most commonly due to KAL1 or FGFR1 mutat

54 a of the olfactory bulb, likely resulting in anosmia, are reminiscent of the symptoms of Kallmann syn

55 te accuracy in identifying participants with anosmia as defined by UPSIT (NASAL-7 area under the rece

56 ctory system function in COVID-19-associated anosmia, as opposed to neuronal infection or neuroinvasi

57 Mice developed anosmia at early time points after infection.

58 % CI, 1.17-3.48) times higher for those with anosmia at the year 8 visit and 2.73 (95% CI, 1.40-5.35)

59 ported neurological complications (including anosmia, ataxia, epilepsy, and neuropsychiatric and cogn

60 to vocalizing pups, as peripherally induced anosmia attenuated maternal proximal orientation toward

61 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B-SIT score < 6).

62 = 34), individuals with isolated congenital anosmia (born without olfactory bulbs) were used as a le

63 ignal transduction occur too late to trigger anosmia, but may contribute to the duration of the olfac

64 Inborn olfactory loss, or congenital anosmia (CA), is relatively rare and there is a knowledg

65 e period with a significantly higher risk of anosmia, cardiac dysrhythmia, diabetes, genitourinary di

66 re more likely to be found to have objective anosmia compared with participants with no history of he

67 (such as rapid eye movement sleep disorder, anosmia, constipation and depression) appear at prodromi

68 pared to controls, individuals with acquired anosmia displayed significantly stronger dynamic functio

69 ction, fatigue and muscle weakness, anxiety, anosmia, dysgeusia, headaches, difficulty in concentrati

70 preceding the PCR testing date, we identify anosmia/dysgeusia (27.1-fold), fever/chills (2.6-fold),

71 positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, in

72 he week prior to PCR testing, in addition to anosmia/dysgeusia, constitutes the earliest EHR-derived

73 Anosmia, fever, and myalgia were the only symptoms assoc

74 prognosis of patients with COVID-19-related anosmia for 1 year after diagnosis.

75 cificity in discriminating participants with anosmia from participants without.

76 cificity in discriminating participants with anosmia from participants without.

77 the angular gyrus, individuals with acquired anosmia had stronger connectivity from the angular gyrus

78 the emergence of Omicron, the prevalence of anosmia has dropped, reducing interest for Omicron patho

79 ho displayed additional phenotypes including anosmia, hearing loss, and intellectual disability.

80 though olfactory cilia dysfunction can cause anosmia, how their differentiation is programmed at the

81 and additional features (fatigue, insomnia, anosmia, hypersalivation and rapid-eye-movement sleep be

82 Apathy, REM sleep behaviour disorder, anosmia, hypersalivation, and cognitive decline were all

83 g in patients with CA or idiopathic acquired anosmia (IA) in comparison to normosmia controls (NC) du

84 Isolated congenital anosmia (ICA) is a rare condition that is associated wit

85 istic models that can explain the widespread anosmia in COVID-19 patients.

86 Y maze and a new method to induce peripheral anosmia in ferrets, we assessed the contribution of cons

87 his study, we developed a behavioral test of anosmia in SARS-CoV-2-infected hamsters.

88 r matches a known locus mediating a specific anosmia, indicating the anosmia may be due directly to t

89 For example, anosmia is a common presentation, and many patients with

90 up to 30% of COVID-19 cases, although total anosmia is relatively rare.

91 dies have suggested mechanisms driving acute anosmia, it remains unclear how SARS-CoV-2 causes persis

92 ) deficiency, which is often associated with anosmia (Kallmann syndrome, KS).

93 hic hypogonadotropic hypogonadism (IHH) with anosmia (Kallmann syndrome; KS) or with a normal sense o

94 hypogonadotropic hypogonadism (nIHH) or with anosmia [Kallmann syndrome (KS)].

95 ith the most common neurobehavioral symptoms anosmia (loss of smell) and fatigue.

96 Anosmia, loss of smell, is a prevalent symptom of SARS-C

97 mediating a specific anosmia, indicating the anosmia may be due directly to the loss of receptors.

98 Anosmia may be explained by several mechanisms driven by

99 ization of mammalian ciliated cells and that anosmia might be a useful determinant of other pleiotrop

100 may experience persistent severe hyposmia or anosmia more than 1 year from the onset of symptoms, sug

101 s positively associated only with persistent anosmia (odds ratio, 2.72; 95% CI, 1.66-4.46), even when

102 The impact of anosmia on quality-of-life (QoL) for patients with aspir

103 d headache (1385 of 3732 patients [37%]) and anosmia or ageusia (977 of 3700 patients [26%]).

104 fever 37.8 C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second d

105 In 7273 individuals with anosmia or at least three symptoms, seroprevalence range

106 these defects are not secondary responses to anosmia or developmental defects, we generated a conditi

107 Furthermore, COVID-19-like symptoms, but not anosmia or dysgeusia alone, were associated with subsequ

108 Anosmia or dysosmia developed more slowly in 15 (83%) pa

109 y classify participants as having functional anosmia or normosmia.

110 er of 37.8 C or higher, shortness of breath, anosmia, or ageusia).

111 function, rapid eye movement sleep behavior, anosmia, or neurogenic bladder.

112 ; hypertension, OR, 1.29; 95% CI, 1.26-1.31; anosmia, OR, 2.16; 95% CI, 1.59-2.93; and parasomnias (i

113 occurring only in individuals with specific anosmias, perhaps only to androstenone.

114 or symptoms, sometimes by years, and include anosmia, problems with gastrointestinal motility, sleep

115 e imaging (fMRI) studies consistent with the anosmia reported in Na(v)1.7 loss-of-function patients.

116 lidate 45 household items into 2 short Novel Anosmia Screening at Leisure (NASAL) assessments, NASAL-

117 terized by adult-onset retinitis pigmentosa, anosmia, sensory neuropathy and phytanic acidaemia.

118 carriers and non-carriers were screened for anosmia, severe hyposmia, and dementia.

119 common presentation, and many patients with anosmia show no or only minor respiratory symptoms(1).

120 syndrome (hypogonadotropic hypogonadism and anosmia), stereotyped midface hypoplasia, intellectual d

121 ing patients with COVID-19 range widely from anosmia, stroke, encephalopathy/encephalitis, and seizur

122 sociated with PD: sensory impairments beyond anosmia, such as hearing loss (OR, 1.14; 95% CI, 1.09-1.

123 ior to threat conditioning (without inducing anosmia), suggesting that both regions are critical for

124 c hypogonadism, which may be associated with anosmia (the Kallmann syndrome) or with a normal sense o

125 Anosmia, the loss of smell, is a common and often the so

126 Anosmia, the loss of the sense of smell, is one of the m

127 Among patients with anosmia, there was a significant association between olf

128 riate modeling demonstrated severe microsmia/anosmia was associated with 1.75 (95% CI, 1.09-2.80) tim

129 12 [31.1%] vs 36 [11.7%]; P < .001), whereas anosmia was more prevalent among nonhospitalized than am

130 Metyrapone-induced anosmia was restricted to the pheromone detectors in P.

131 mes were not significantly different, except anosmia, which was more common after COVID-19 (odds rati

132 mptomatic forms of SARS-CoV-2 (identified by anosmia with either fever, breathlessness or cough) pres